USFDA Inspection Concludes at Zydus' Biologics Injectable Plant in Ahmedabad
Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (USFDA) completed a GMP surveillance inspection at the company's Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad. The inspection process took place from April 27 to May 5, 2026.The inspection concluded with the recording of seven observations. The company confirmed that, during the review, there were no observations related to data integrity.
Zydus Lifesciences stated that the company plans to work closely with the USFDA to address all noted observations in an expeditious manner.
ZYDUSLIFE Stock Price Movement
Shares of Zydus Lifesciences Limited are edging higher to ₹930.3 as of 11:46 AM today, rallying by 1.98% in live trading. The stock is seeing robust institutional interest, with a volume of 487,447 shares circulating in the live market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.